文献速递神经肿瘤

IDH1野生型原发性胶质母细胞瘤全切除后出现意外短期生存患者的临床与分子特征

Clinical and molecular features of patients with IDH1 wild-type primary glioblastoma presenting unexpected short-term survival after gross total resection.
PubMed 文献 · J Neurooncol · 2024-06-05

该研究分析5个独立队列共446例接受全切及放疗联合替莫唑胺(TMZ)治疗的IDH1野生型原发性胶质母细胞瘤患者,定义总生存≤12个月为短期生存者(STS)。各队列均出现意外STS,占15.0%-23.9%;STS组与非STS组在MGMT、TERT、EGFR、PTEN、CDKN2A等主要基因改变上无显著差异;STS组治疗早期非局部复发比例较高,K队列为60.0%,V队列为43.5%。

要点

  • 各队列全切后均出现意外短期生存者,占15.0%-23.9%
  • STS组与非STS组在MGMT、TERT、EGFR、PTEN、CDKN2A等主要基因改变上无显著差异
  • STS组治疗早期非局部复发比例较高,K队列60.0%,V队列43.5%

核心结论

  • IDH1野生型原发性胶质母细胞瘤全切后出现意外短期生存并不少见,此类肿瘤倾向于早期非局部复发。
  • STS组未发现显著基因改变,提示这些主要改变是胶质母细胞瘤的特征,而非复发模式或意外STS的可靠预测因素。

研究设计与样本

  • 分析5个独立队列共446例接受全切的胶质母细胞瘤患者,包括Kitasato大学83例(K队列)、共同研究者验证队列148例(V队列)、关西中枢神经系统肿瘤分子诊断网络66例、癌症基因组图谱109例、胶质瘤纵向分析联盟40例。
  • STS定义为全切后接受放疗及同步和辅助替莫唑胺(TMZ)治疗、总生存≤12个月。

主要发现

  • 全部队列均出现意外STS,范围为15.0%-23.9%。
  • STS组与非STS组在MGMT、TERT、EGFR、PTEN和CDKN2A等主要基因改变上无显著差异。
  • STS组治疗早期非局部复发发生率较高,K队列为60.0%,V队列为43.5%。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: This study investigated the factors influencing short-term survivors (STS) after gross total resection (GTR) in patients with IDH1 wild-type primary glioblastoma. METHODS: We analyzed five independent cohorts who underwent GTR, including 83 patients from Kitasato University (K-cohort), and four validation cohorts of 148 patients from co-investigators (V-cohort), 66 patients from the Kansai Molecular Diagnosis Network for the Central Nervous System tumors, 109 patients from the Cancer Genome Atlas, and 40 patients from the Glioma Longitudinal AnalySiS. The study defined STS as those who had an overall survival ≤ 12 months after GTR with subsequent radiation therapy, and concurrent and adjuvant temozolomide (TMZ). RESULTS: The study included 446 patients with glioblastoma. All cohorts experienced unexpected STS after GTR, with a range of 15.0-23.9% of the cases. Molecular profiling revealed no significant difference in major genetic alterations between the STS and non-STS groups, including MGMT, TERT, EGFR, PTEN, and CDKN2A. Clinically, the STS group had a higher incidence of non-local recurrence early in their treatment course, with 60.0% of non-local recurrence in the K-cohort and 43.5% in the V-cohort. CONCLUSIONS: The study revealed that unexpected STS after GTR in patients with glioblastoma is not uncommon and such tumors tend to present early non-local recurrence. Interestingly, we did not find any significant genetic alterations in the STS group, indicating that such major alterations are characteristics of GB rather than being reliable predictors for recurrence patterns or development of unexpected STS.

来源:J Neurooncol,查看原文。版权归原作者所有。

引用

  1. Toyoda M, Shibahara I, Shigeeda R, et al. Clinical and molecular features of patients with IDH1 wild-type primary glioblastoma presenting unexpected short-term survival after gross total resection. J Neurooncol. 2024. PMID: 38839702. doi:10.1007/s11060-024-04687-2

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。